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Biological properties of nerve growth factor
Nerve growth factor (NGF), the prototypical member of the neurotrophin family, is an important molecule that regulates neuronal survival and differentiation. [1] [2] [3] NGF and other members of the neurotrophin family, including brain-derived growth factor (BDNF) and a series of structurally related proteins NT3 and NT4/5, support the survival of specific types of neurons and neurotransmitter systems, and are synthesized and secreted by cells that are the targets of specific innervating neurons. 4 NGF responsiveness has been demonstrated for a number of nervous system regions, including the basal forebrain, substantia nigra, brain stem, cortex, and spinal cord. [1] [2] [3] Other neurotrophic factors have also been shown to promote the survival of particular neuronal subpopulations; these factors include the glial cell line-derived neurotrophic factor (GDNF) for dopaminergic neurons and motor neurons, and the ciliary neurotrophic factor (CNTF) for motor and spinal cord neurons.
NGF plays a role in the maintenance of the cholinergic neurotransmitter system in specific populations of neurons, including a group of cholinergic forebrain neurons. [1] [2] [3] Deprivation of NGF to the cholinergic forebrain neurons can result in the decrease of somal size and choline acetyltransferase levels; subsequent delivery of NGF to these neurons can reverse these morphological and biochemical alterations. This response forms the rationale for the potential gene delivery of NGF into Alzheimer's disease patients, who consistently demonstrate a loss of functional basal forebrain cholinergic neurons. 4 In addition, NGF plays key roles in the initiation of axon growth, synaptic rearrangement, and dendritic sprouting, and prevents sympathetic and sensory neuronal death during development. [1] [2] [3] Studies conducted in rats demonstrate that NGF can prevent lesion-induced basal forebrain cholinergic neuronal degeneration, and can reverse age-related degeneration in the same set of neurons. 3 
Nerve growth factor expression in brain transplants
Neurodegenerative diseases, including Parkinson's disease and Alzheimer's disease, consist of a complex group of brain disorders exhibiting a common pathological event -neuronal cell death. The use of traditional pharmacological therapy for neurological diseases is inherently restricted by the blood-brain barrier, which limits access of large molecules to the brain. Genetic therapy approaches have enabled neuroscientists and clinicians to begin development of potential approaches to overcome problems of dosage and drug targeting effects associated with pharmacotherapy. 5, 6 For instance, gene transfer into a specific brain structure, achieved by either grafting of genetically modified cells or with the use of injected viral vectors, should allow localized and controlled expression of the transgene product to its therapeutic target. 7 Fetal brain material was among the first sources of tissue demonstrated to provide neurotrophic support in CNS implants. Compared with fetal neurons, adult neu-rons do not survive transplantation and do not express the same degree of plasticity. Fetal nigral neurons have been utilized to reverse dopamine deficiency in animal models of Parkinson's disease, and attenuate apomorphine-induced rotational behavior in rats with unilateral nigrostriatal lesions. [8] [9] [10] Fetal cholinergic implants have also reversed cognitive deficits of maze learning in rats with lesions of the fimbria-fornix, in an animal model of Alzheimer's disease. 11, 12 In addition, adrenal tissue has been used as an alternative source of dopamine producing cells, 13, 14 but does not appear to ameliorate deficits observed in animal models of Parkinson's disease. 15, 16 More recent efforts have focused on the development of cultured or genetically modified cells that can serve as replacement cells for degenerating neurons in neurodegenerative disorders, or the use of cells capable of releasing specific trophic factors in brain-damaged regions. 17, 18 Compared with the use of fetal cells in transplantation, cultured or genetically modified cells retain several advantages, including control of the quality and quantity of the transplanted cell and provision for genetic and biochemical characterization before implantation. The potential utility of established cell lines as donor tissue for neural implants has been demonstrated in several species, including non-human primates; 19 IMR-32 neuroblastoma cells, rendered amitotic and differentiated in vitro, survived for over a year following hippocampal implantation in fimbria-fornix lesioned monkeys. Furthermore, the addition of exogenous trophic factors such as NGF or basic fibroblast growth factor (bFGF) enhances survival and function of grafted adrenal chromaffin cells, 20, 21 and protects septo-hippocampal cholinergic neurons from lesion-induced degeneration 22, 23 and from glucose deprivation-induced neurofibrillar tangle expression.
Genetically modified donor cells have been utilized in a number of neural transplantation model systems. 17, 18, 24 Fibroblast and neuroblastoma cell lines, genetically modified to express tyrosine hydroxylase, produce dopamine and attenuate rotational behavior upon implantation into denervated rat striatum. 25 Fibroblasts, genetically modified to express rodent or human NGF, have been demonstrated to express NGF following implantation into the deafferented septohippocampal cholinergic projection, with subsequent survival and regeneration of axotomized septal cholinergic neurons. 26, 27 Genetically modified NGF-expressing cells have been demonstrated to express transgenes for up to 10 weeks after intracerebral implantation. 27 Even though parallel studies have demonstrated survival of NGF-expressing cerebral endothelial cells upon implantation into the striatum and nucleus basalis of adult rats, for 1 year without the formation of tumors, 28 such cells retained only limited transgene expression (3-8 weeks) and hence may have only limited applicability to human gene therapy approaches. In an attempt to extend transgene expression in a similar system, NGFproducing primary fibroblasts grafted into the striatum have been demonstrated to survive for at least 6 months following transplant without producing tumors. 29 Hippocampal neurons are protected by genetically modified NGF-producing fibroblasts during ischemia in a rat model. 30 Following hippocampal deafferentation, implanted NGF-secreting primary fibroblasts promoted cholinergic reinnervation and decreased ectopic ingrowth of sympathetic fibers, with significant improvement of locomotor habituation task performance. 31 In other studies, following partial immunolesion of the rat basal forebrain, implantation of NGF-secreting fibroblasts reversed lesion-induced reductions in cholinergic markers. 32 Furthermore, intraparenchymal grafts of monkey fibroblasts genetically modified to produce NGF appears to prevent injury-induced degeneration of cholinergic neurons. 33 More recently, NGF-secreting neural stem cells implanted in the adult rat striatum have been demonstrated to ameliorate ischemia-induced neuronal death. 34 In addition, human fetal astrocytes, transduced with an amphotropic retrovirus recombinant harboring mouse ␤-NGF, was demonstrated to deliver biologically active nerve growth factor, and may be useful for delivery of trophic factors to the human CNS. 35 Several studies have demonstrated the additional requirement of providing suitable cellular matrices to support the regeneration of damaged neurons in the CNS. Damaged adult septal neurons can regenerate when NGF is provided along with a suitable cellular substrate. 36 In addition, cholinergic neurons have been demonstrated to re-establish connection with the hippocampus following fimbria-fornix transection, if a suitable cellular growth substrate is placed in the lesion cavity. [37] [38] [39] Moreover, NGF-producing primary fibroblasts suspended in a semi-solid collagen gel provided the trophic and substrate support to permit growth of acetylcholinesterase-immunoreactive fibers and to re-establish synaptic contacts with granule cells in the hippocampus. 36 Polymers have been utilized to encapsulate grafted cells, and thereby control the release of trophic factors or neurotransmitters (eg mini-dopamine pump). 40 In experimental studies, NGF-expressing hamster kidney cells (BHK-hNGF) were encapsulated in hollow fibers of acrylnitrile vinyl chloride copolymer and implanted in the lateral ventricle or caudate-putamen of rats. 41, 42 NGF secretion and support was provided for long periods (13.5 months). Robust sprouting of cholinergic fibers was observed within the frontal cortex and lateral septum proximal to the implant, indicating that encapsulated xenogeneic cells provided an effective method for longterm delivery of NGF within the CNS. The polymer shields the implanted cells from the host's immune system, and can minimize the potential for rejection of xenogeneic cells. In studies conducted by the same investigators, 43 co-grafts of adrenal medula and the NGFexpresser BKH-hNGF cell line increased the survival of implanted adrenal chromaffin cells by 20-fold, and resulted in significant decreases in apomorphine-induced rotational behavior. Additionally, the same polymerencapsulated cells were transplanted into the fimbriafornix-lesioned rat 44 and were demonstrated to provide nearly complete protection of axotomized medial septal cholinergic neurons for 6 months in vivo. The implantation of these polymer-encapsulated NGF-secreting fibroblasts can also attenuate the behavioral and neuropathological consequences of quinolinic acid injections in rodent striatum. 41 Cynomolgus macaques, containing unilateral transection of the fornix, were implanted with the BHK-hNGF cell line in the lateral ventricle; these monkeys lost only a modest number of cholinergic neurons, and exhibited dense sprouting of cholinergic fibers within the septum. 45 Polymer-encapsulated schwannoma cells expressing human NGF can also promote the survival of cholinergic neurons following fimbria-fornix transection. 46 
1650
Co-grafting of adrenal chromaffin cells and primary NGF-producing skin fibroblasts in dopamine-denervated striatum resulted in transdifferentiation of the chromaffin cells in vivo, displaying characteristics of mature sympathetic neurons. 47 In similar studies, co-grafting of adrenal chromaffin cells with either the distal stump of the pretransected peripheral nerve or with primary type 1 astrocytes into the striatum of parkinsonian mice (either MPTP-induced or the 6-hydroxydopamine lesioned rat) increased chromaffin cell survival. 48, 49 Other ex vivo gene transfer protocols have been conducted to investigate the effect of implanting NGFsecreting cells in aged subjects. The high NGF-secreting sub-clone of the hippocampus-derived HiB5 cell line, 50, 51 demonstrated to be one of the most efficient NGF producer cell lines, was implanted in the basal forebrain of cognitively impaired, aged rats. 50 These conditionally immortalized cells, which express the temperature-sensitive mutant allele of the SV40 large T-antigen, are propagated at the permissive temperature (33°C), but become differentiated at the non-permissive temperature of the rat brain. 51 This implant induced sprouting of cholinergic axons after transplantation into the intact striatum, and can provide complete protection of axotomized cholinergic septal neurons after transplantation into the septum of fibria-fornix-lesioned rats. Implantation of NGFsecreting cells reverses spatial learning and memory impairments in aged rats. 52 Capsules containing BHKhNGF were implanted bilaterally in each lateral ventricle of learning-impaired aged rats; subjects containing implants demonstrated improved performance in a repeated acquisition version of the Morris water maze spatial learning task. 52 In other studies, NGF-secreting cells were implanted in the nucleus basalis of both aged and young rats. 7 Amelioration of behavioral deficits was observed in aged rats; however, implantation of NGFsecreting cells in normal young rats resulted in a transient memory impairment and hypertrophy of low-affinity NGF receptor-containing neurons. 7 Alternatively, parallel experiments conducted by other investigators 53 demonstrate improved spatial learning and task performance in all NGF-supplemented rats, including young adults. In recent studies, NGF secretion from immortalized neural progenitor cells implanted in the rodent basal forebrain prevented cholinergic neuron atrophy and cognitive impairment in aged rats. 54 In studies using other neurotrophic factors, fibroblasts were genetically modified to express high levels of neurotrophin-3 (NT-3) constitutively, and subsequently implanted in a 6-hydroxydopamine lesion rat model that resembles the pattern of cell loss found in Alzheimer's disease. 55 These studies demonstrate that NT-3, but not other neurotrophins including NGF, NT-4, and BDNF, can promote the survival of adult central noradrenergic neurons of the locus coeruleus in vivo. 55 BDNF-secreting cells implanted in the nucleus basalis magnocellularis region and in the striatum induced a hypertrophic response of cholinergic neurons. 56 In other studies, ciliary neurotrophic factor, provided by co-grafts of genetically modified glioma cells, promotes the terminal differentiation of v-myc immortalized sympathoadrenal progenitor cells in vivo. 57 Basic FGF was also capable of promoting the transdifferentiation of adrenal chromaffin cells implanted in rats with unilateral 6-hydroxydopamine lesions. 58 Fibroblasts genetically modified to produce glial-derived neurotrophic factor (GDNF) were implanted into the striatum of aged rats; improved motor activity was observed in a series of speed, endurance, and coordination tests. 59 To investigate the potential utility of NGF-expresser grafts in treatment of adult spinal cord injury, primary rat fibroblasts were genetically modified to produce human NGF, and then grafted and established on to lesioned adult rat spinal cord for periods of up to 1 year in vivo. 60 These studies demonstrate robust growth of sensory and noradrenergic neurites observed in the lesioned spinal cord. Grafts of fibroblasts genetically modified to secrete NGF, BDNF, NT-3, or basic fibroblast growth factor (bFGF) were found to elicit differential responses in the adult rat spinal cord; NGF, NT-3, and bFGF, but not BDNF-secreting grafts were found to promote extensive growth of sensory neurites of dorsal root origin. 61 Interestingly, studies conducted by other investigators 62 demonstrate rapid recovery of rats with moderate spinal cord injury following implantation with either NGF-or BDNFsecreting fibroblasts. Polymer-encapsulated CNTF has also been proposed for potential application in amyotrophic lateral sclerosis. 63 In addition, in an in vitro experiment, retinal ganglion cell survival is promoted by genetically modified astrocytes designed to secrete BDNF; 48 presumably, this capacity for enhanced survival may be of importance in Alzheimer's patients who have decreased BDNF mRNA levels in the hippocampus. In other experiments, in an attempt to deliver NGF to the peripheral nervous system, NGF-engineered neuritogenic T lymphocytes attenuated experimental autoimmune neuritis. 64 NGF can also reverse cholinergic atrophy in a Down syndrome model (Ts 16-induced) of age-related neurodegeneration. 65 Ts 16, trisomy of chromosome 16 in the mouse, is a potential model for Ts 21 in the human, which has been implicated in Down's syndrome.
Regulated and inducible eukaryotic promoter systems for potential use in ex vivo gene therapy
Future strategies may optimally require precise regulatory control of transgene expression in specific cell targets. 66 Transcriptional targeting, involving the use of cellspecific promoters or enhancers, represents one approach to restrict expression of therapeutic transgenes in a specific cell or tissue. Current applications of transcriptional targeting have been directed to the genetic therapy of cancers and solid tumors using suicide genes, such as the herpes simplex thymidine kinase gene. The promoters for the carcinoembryonic antigen (CEA) and the alpha-fetoprotein (AFP) genes, which appear to be restricted in malignant cells derived from breast, lung, and colorectal cancers and from hepatomas, respectively, have been proposed for selective expression of suicide genes in the treatment of cancers. 66 The CEA promoter can confer restricted expression of heterologous genes; however, the use of this promoter in an in vivo murine tumor regression model proved to be of limited effectiveness. 67, 68 The AFP promoter has been used to regulate thymidine kinase expression in virus vector systems; this promoter was useful in restricting thymidine kinase expression in AFP-producing xenografts and successfully achieved complete tumor regression following gene transduction and ganciclovir treatment. 69 Cis-acting control sequences contained in several other genes, including genes encoding transferrin, synapsin I, neurofilament light, acetylcholine receptor, and the potassium channel, retrict expression to neurons or to brain-specific targets, 66 and may potentially be considered for the directed expression of transgenes in treatment applications of nervous system disorders.
In addition, regulation of transgene expression through the use of inducible promoter systems may be required to achieve appropriate therapeutic doses or to restrict applications to specific time-windows. Transgene expression in brain transplants may be potentially controlled with the use of promoters that can be induced by the addition of exogeneous agents. Some cellular promoters, including the glucocorticoid, metallothionein or heavy metal-responsive promoters, and the cytochrome P450 1A1 promoter, are inducible and may be utilized to regulate transgene expression. [70] [71] [72] Other potential promoters may include the tyrosinase promoter whose activity is restricted to the melanocyte lineage, contains several cyclic AMP-response elements (CREs) and is responsive to cyclic AMP regulators. 73 In addition, the prostate antigen (PSA) promoter is inducible by androgens and growth factors, and the AFP promoter is responsive to glucocorticoids. 74 Some recent strategies now include promoters that are preferentially active during disease states. 75 The vascular endothelial growth factor (VEGF) promoter is up-regulated by hypoxia, which is a pathological condition typically found in solid tumors; VEGF up-regulation is mediated by hypoxia-responsive elements contained in the 5Ј non-translated region of the VEGF gene. 76 Interestingly, similar hypoxia-response elements have been idenified for the endothelial cell nitric oxide synthase promoter, 77 and the rat Grp78 protein promoter is anoxiainducible and demonstrated to drive high level gene expression in solid tumors. 78 Radiation-inducible promoters may also be potentially utilized for localized expression of suicide genes. The early response gene-1 (EGR) promoter is radiationinducible, and has been used to drive tumor necrosis factor expression in transduced tumors; 79 interestingly, both the induced factor itself, and radiation treatment synergistically resulted in more effective tumor eradication with no increase in toxicity. 79 In an analogous system, the MDR-1 promoter contains drug response elements sensitive to anticancer agents, and may potentially be utilized to concurrently drive suicide gene expression during chemotherapeutic treatment. 80 Potential use of nonmammalian or synthetic inducer and promoter systems in ex vivo gene therapy Nonmammalian transcriptional control systems have been given recent consideration for transgene regulation in genetic therapy approaches. 66 One consequence of using inducible mammalian promoters for regulation of transgene expression is the undesired transcription of correlated endogeneous genes. In addition, endogeneous regulators for specific promoters may also interfere with the desired activation of the transgene by the induction agent. In the tetracycline operon, transcription is negatively regulated by interaction of the tet repressor protein to operator sequences; transcriptional repression is reversible by binding of tetracycline to the repressor. [81] [82] [83] Furthermore, the tet repressor system has been successfully converted into the 'tet-off' and 'tet-on' systems. 81, 82 In the 'tet-off' system, the tet repressor is fused with the VP16 transactivator sequence to create a chimeric transactivating factor capable of positive transcriptional activation of genes containing the tet operator; subsequent interaction of tetracycline with the chimeric factor will turn off transcription. In the 'tet-on' system, a mutant form of the chimeric transactivating factor will bind to tet operator sequences in the presence of tetracycline to activate transcription. The 'tet-on' system has been utilized to control the transcription of the pro-opiomelanocortin gene in encapsulated cells implanted within the cerebrospinal fluid space of rats. 84, 85 The tetracyclinerepressible system has been successfully demonstrated in the tissue-specific modulation of erythropoietin (Epo) secretion in genetically modified myoblasts and in vivo in mice receiving somatic cell transplants. 86, 87 In this system, myoblasts were transduced with two retroviral vectors, one containing the murine Epo cDNA under the control of a minimal cytomegalovirus promoter containing repeats of the tet operator, and the second containing the chimeric transactivator sequence (VP16, tet repressor fusion recombinant) under the control of the muscle-specific human desmin promoter. 86 Tissue-specific modulation of Epo secretion upon tetracycline administration was observed in mice following transplantation of the genetically modified myoblasts. 86 Furthermore, Epo modulation could undergo iterative switching over a 5 month period depending on the absence or presence of drug in the animals' drinking water. 87 Other more classical transcriptional regulatory systems include the lac operon and the bacteriophage T7 RNA polymerase gene promoter system. 88 As in the tetracycline operon, LacZ transcription from the lac operon is negatively controlled by a constitutively expressed repressor protein that binds to LacZ operator sequences, 89 this transcriptional repression can be reversed by addition of ␤-galactosidase substrate, which binds to the lac operon and inactivates the repressor protein. In an analogous system containing two inter-dependent recombinants and drawing upon elements of the lac operon, the bacteriophage T7 RNA polymerase gene in one recombinant is transcriptionally controlled by the LacZ promoter, and the therapeutic transgene in a second recombinant is controlled by a promoter containing T7 RNA polymerase sites. In the presence of ␤-galactosidase substrate, the lac repressor is inactivated and the T7 polymerase gene is transcribed, allowing subsequent transcription of the therapeutic transgene.
In addition to the tet and lac operon systems, other nonmammalian genetic regulatory systems might be potentially developed as inducible systems for gene therapy. These additional systems include the yeast Saccharomyces cerevisiae DNA binding protein GAL4, the insect hormone ecdysone, and the yeast protein Leu3. 43, 90, 91 Tetracycline-based systems have distinct disadvantages, including the requirement of continual tetracycline treatment to activate or repress transcription and the slow physiological clearance of this antibiotic leading to imprecise regulatory control.
Several investigators have exploited the transactiv-ational control abilities of mammalian steroid receptors in producing synthetic regulatable systems. 66 In mammalian systems, nuclear steroid hormone receptors are activated by ligand binding; these activated receptors then recognize DNA elements in hormonally regulated genes to transactivate gene transcription. To achieve higher specificity in synthetic systems, the DNA binding domain (DBD) of the steroid receptor can be replaced with a non-mammalian correlate, and the ligand binding domain (LBD) modified to recognize synthetic but not endogeneous steroids. In one example, the DBD of the yeast GAL4 protein was fused to the LBD of the human estrogen receptor to produce an estradiol-responsive transactivator with high transcriptional inducibility. 90 Since mammalian cells do not appear to express Gal4-like activity or endogenous estrogen receptor, this estradiolresponsive transactivator system is highly selective and does not appear to activate endogeneous genes. In this induction system, Braselmann et al 90 created a synthetic Gal4 promoter consisting of multiple Gal4-binding sites, and a more potent transactivator fusion recombinant containing the DBD of Gal4, LBD of the human estrogen receptor, and the strong transactivator domain of the herpes simplex virus protein VP16. This estradiol-responsive transactivator system was used to drive expression of Gal4-responsive fos gene recombinants in rat fibroblasts, leading to rapid and maximal induction of fos within 1-2 h of estrogen treatment and estrogen-dependent transformation. 90 In other studies, the LBD of the estrogen receptor was mutagenized by random point mutations to create a transactivator responsive to synthetic nontoxic pharmaceutical compounds, with decreased responsiveness to estradiol. 91 The human progesterone receptor has also been recently modified into a synthetic regulatable expression system. A mutant progesterone receptor that can bind the synthetic progesterone antagonist RU486 but not progesterone itself was used to create an artificial transactivator. 92 The LBD of the mutant progesterone receptor was fused to the GAL4 DBD to form a RU486-responsive transactivator capable of inducing transcription of genes containing GAL4-responsive promoters. This synthetic transcription factor was activated with RU486 in cells transplanted into rodents, and capable of transactivating reporters containing GAL4-responsive promoters in vivo. In addition, for potential application in the nervous system, Oligino et al 93 have utilized replication-defective herpes simplex virus (HSV) vectors to express the recombinant transactivator GAL4:VP16, capable of activating transcription of a reporter gene containing promoter elements of the adenovirus E1b gene and also Gal 4 DNA binding sites. This reporter gene was successfully activated in neurons following direct intracranial inoculation into the rat hippocampus.
Another alternative to tetracycline-based systems utilizes the insect molting hormone ecdysone as a potential inducer. Metamorphosis in Drosophila melanogaster is triggered by the interaction of ecdysone with a functional heterodimeric ecdysone receptor. No et al 43 have created an ecdysone-inducible gene expression system for use within cultured mammalian cells or transgenic mice by co-expression of the retinoid X receptor (RXR), mutated ecdysone receptor-VP16 fusion recombinant (N-terminal truncation of the ecdysone receptor fused to the activation domain of herpes simplex virus VP16), and a reporter recombinant containing an ecdysone-responsive promoter. In mammalian cell systems, the RXR and mutated ecdysone receptor will heterodimerize and transactivate ecdysone-responsive promoters in the presence of ecdysteroids. When compared with the tetracycline system, ecdysteroid-activated promoters result in greater inducibility (four orders of magnitude higher) and lower basal activity. Other advantages favoring the use of ecdysteroids in mammals include its low toxicity, efficient penetrance into tissues, short half-lives and expedited physiological clearance, and lack of any known natural target or effect in mammalian physiology.
Recently, scientists at ARIAD Gene Therapeutics (Cambridge, MA, USA) have described a new gene regulation system consisting of a synthetic bipartite transcription factor and a rapamycin inducer. 94, 95 This system consists of two transcription factor fusion proteins, one containing the transactivator domain of the NFB p65 protein fused to hFRB, the rapamycin binding domain of the human protein FRAP, and the second consisting of the DNA binding domain of the nonmammalian protein ZFHD-1 fused to human protein FKBP, which also binds rapamycin. 94, 95 Rapamycin can serve as a dimerizer or adaptor to form a fully functional bipartite transcription factor, recognizing promoters containing ZFHD-1 DNA binding sites. 94, 95 This system has distinct advantages, including low background and high inducibility, positive induction with an orally bioavailable drug, modularity of system components to increase versatility, and the exclusive expression of human proteins that would reduce immune recognition and rejection. The low background is exceptional, due to the lack of recognition of the ZFHD-1 DNA binding sites to endogeneous mammalian transcription factors, and the inability of the two transcription factor fusion recombinants to recognize each other in the absence of rapamycin. One potential disadvantage in this system is the direct use of rapamycin, an analogue of the natural immunosuppressive compound FK506, and its potential immunosuppressive action in humans. In initial experiments first describing this system, reporter vectors were constructed to synthesize secreted alkaline phosphatase (SEAP), under the control of a cytomegalovirus early promoter containing 12 ZFHD-1 DNA binding sites, and were subsequently transfected into human HT 1080 fibrosarcoma cells. 94 In vitro experiments demonstrate that SEAP production was A, B, C and F minimally induced at 500 pm rapamycin and maximally induced at 10 nm, with a 10 000-fold maximum induction ratio. 94 In other experiments, a human growth hormone (hGH) gene reporter was constructed consisting of a minimal SV40 promoter and eight ZFHD-1 DNA binding sites. 95 Cells containing the bipartite transcription factor fusion recombinants and the hGH reporter recombinant were implanted into immunodeficient nude mice and stimulated by administration of rapamycin. Rapamycin induced serum hGH in these animals in a dose-dependent fashion, reaching a maximum of 10 ng/ml hGH at 10 mg/kg rapamycin. 95 Controlled manipulation of several factors, including the number of transplanted cells, and the activity and pharmacokinetics of both rapamycin and hGH, influenced the level of circulating hGH in vivo. 95 The rapamycin-inducible system was refined for use in in vivo applications, with the development of two adenoassociated viral (AAV) vectors, one expressing both transcription factor fusion recombinants, and the other containing an erythropoietin (Epo) reporter under the control of a promoter containing ZFHD-1 DNA binding sites. 96 A mixture of the two AAV recombinants was injected into the skeletal muscle of immunodeficient and immunocompetent mice; rapamycin administration (10 mg/kg) resulted in an immediate 100-200-fold induction of circulating plasma Epo that returned to baseline levels within 14 days following drug administration. 96 In addition, these animals exhibited no diminution in Epo inducibility using repeated rapamycin administrations, up to 6 months following the initial administration. These AAV vectors were also injected in the quadricep muscles of rhesus monkeys; regulated expression of Epo was also achieved with rapamycin administration (50-fold induction following single administration, with return to baseline Epo levels within 14 days). Epo inducibility could be sustained with rapamycin re-challenge at up to 3 months following the initial administration; after 3 months, Epo inducibility dropped dramatically, potentially due to a decrease in in vivo expression of the transcription factor components or to elimination of the transcription factors by immunorejection of the antigenic protein domains (influenza virus hemagglutinin and SV40 nuclear localization sequence) incorporated into the amino-termini of these transcription factors. 96 
Figure 1 Treatment of JW PC12 cell line and transfectant clone NP33 to assess NGF and zinc-responsiveness, respectively. JW cells were plated, maintained on extracellular-matrix (ECM) plates, and treated with 0, 50 or 400 ng/ml (Panels A, B, and C, respectively) of NGF for 24 h. Note neurite formation in panels B and C (see arrows). Filaments observed in the background of panels A, B, and C are the extracellular matrix support, and are not neurite extensions. Arrows in panels B, C, D, and F denote representative neurites. (D) Transfectant clone NP 33 was plated and maintained on extracellular-matrix plates, and incubated in the presence of 400 m zinc sulfate for 6 h followed by an additional 18 h in zinc-free medium. Note neurite extensions indicative of synthesis and neurotransformation effect of NGF transgene product. Transfectants containing the pMEP 4 vector (without NGF insert) did not undergo neurite extension in the presence of zinc sulfate (data not shown). (E and F) Representative transfectant clones containing the NGF transgene, in the absence of zinc sulfate, that remained undifferentiated (E) or had undergone autodifferentiation (F, presumably in response to significant levels of NGF mRNA transcribed from the leaky metallothionein promoter). Scale bars (in panels

Metallothionein promoter system
Metallothioneins are small cysteine-rich proteins that selectively bind heavy metals, including zinc, cadmium, and copper, and have been implicated in heavy metal detoxification and radical scavenging functions. 97, 98 MT gene regulation is induced by the addition of heavy metals, and is controlled by metal regulatory elements (MREs) contained in the promoter in multiple, non-identical copies. 97, 98 Both the mouse MT-1 and human MTlla genes contain at least two functional MREs in an imperfect 12-nucleotide duplication (proximal MRE: centered at positions −46 and −49 for the human and mouse, respectively; distal MRE: centered at positions −114 or −145 for the mouse and human, respectively). The mouse MT-1 gene also contains partial repeats of this sequence in the inverse orientation at a minimum of three other locations in the MT promoter region (sites centered at positions −160, −134, and −62). Additional mutagenesis experiments have implicated sequences outside the MREs as playing important roles in determining transcriptional efficiency; the GC-rich region between the two metal response elements is believed to serve as a key contributor in the regulation of basal transcription of the metallothionein gene. 97, 98 The MT genes contain typical TATA boxes immediately downstream of the proximal MRE.
97,98
PC12 cell line as donor material for CNS transplants
The pheochromocytoma PC12 cell line, derived from the rat adrenal gland, has been utilized as donor tissue in animal models of Parkinson's disease. These cells are neural crest-derived and are pluripotent, retaining the capacity to synthesize catecholamines (including dopamine), acetylcholine, and the neurotransmitters somatostatin, enkephalin, and dynorphin. Addition of NGF to PC12 cells results in mitotic arrest and induces neurotransformation with concurrent development of neurites. NGF-treated PC12 cells also undergo extensive cytoskeletal remodeling and express neurofilament (NF) subunit and vimentin filament (VF) protein. 99 Neurosecretory granules are redistributed to the neurites. The morphological differentiation of PC12 cells are accompanied by the induction of opioid and muscarinic receptors and sodium channels and with a decreased sensitivity to secretagogues.
While transplanted PC12 cells can ameliorate dopamine deficits in parkinsonian rats, these cells degenerate within 2-3 weeks after implantation, presumably due to lack of sustained NGF availability at the implantation site. 100 Alternatively, in some cases, these cells can develop into tumor masses leading to the death of the host animal. Recently, other laboratories have utilized PC12 cells, genetically modified by retrovirus vectors to express NGF, [101] [102] [103] or polymer-encapsulated to prevent entry of host factors promoting immune destruction, as donor material for rodent striatal grafts. 104 To extend these previous studies, we sought to develop a genetically modified PC12 cell line that can synthesize NGF under the control of an inducible regulator, the metallothionein promoter. When implanted in the brain and stimulated with zinc, these cells will neurodifferentiate, express NGF and tyrosine hydroxylase, and undergo survival through potential autocrine trophic support. Thus, these genetically modified PC12 cells may serve as an excellent source of donor material with the potential of long-term survivability and induced trophic factor expression.
Metallothionein promoter-driven expression of nerve growth factor in rat brain transplants An 812 bp DdeI-PstI coding fragment encompassing the mature ␤-NGF sequence (exons III and IV) 105 was directionally inserted into the eukaryotic expression vector pMEP 4 (Invitrogen, Carlsbad, CA, USA), which contains the zinc-inducible human metallothionein (MT) IIA promoter, SV40 polyadenylation signal, and hygromycin B selectable marker. This NGF expression recombinant was transfected into the JW PC12 cell line using the method of Chen and Okayama, 106 and transfectants were selected and maintained with hygromycin B (800 Units/ml; 10-14 days). The nontransfected JW cell line was found to be highly resistant to the toxic effects of zinc, and to remain viable in medium containing up to 1200 m zinc sulfate (ZnSO 4 ), a concentration of zinc more than sufficient to induce the MT promoter. The JW cell line was found to be highly responsive to NGF; neurites were formed within 24 h of NGF treatment (50 ng/ml or 400 ng/ml) (Figure 1 ; compare panel A with panels B and C). Not unexpectedly, several transfectant clones contained leaky metallothionein (MT) promoters and expressed detectable levels of the NGF transgene mRNA in the absence of zinc (Figure 2a and b) . Interestingly, some of these transfectants containing leaky MT promoters did not auto-differentitate (in the absence of zinc; NP28 and NP33; Table 1 ), indicating that a threshold value of expressed and/or secreted NGF was necessary for neurodifferentiation of PC12 transfectants to occur. Alternatively, some transfectants (NP15 and NP21) produced moderately detectable basal levels of NGF mRNA and auto-differentiated in the absence of zinc.
The proto-oncogene c-fos is one of several immediateearly genes that becomes transcriptionally activated by addition of NGF to PC12 cells, 59 and is important in the up-regulation of the tyrosine hydroxylase gene. To confirm that c-fos mRNA expression could be up-regulated by NGF in our system, we incubated PC12 transfectants in the presence or absence of zinc sulfate and analyzed cfos mRNA expression by Northern blot analyses. Several transfectant clones (NP21, NP22, NP23, and NP33; Figure  2c ) were observed to constitutively express c-fos mRNA in the absence of zinc. While the degree of induction of c-fos transcription, following zinc stimulation, appears to vary among the transfectant clones, inducibility of c-fos expression is readily observed in NGF-expresser transfectant clones NP21 and NP33 (Figure 2c) . Interestingly, clone NP22, which only weakly expressed NGF mRNA under zinc induction, demonstrated only weak induction of c-fos mRNA levels following zinc treatment ( Figure  2c ). In addition, at least one transfectant (NP23) contained an abnormally sized, non-inducible NGF mRNA that was incapable of stimulating c-fos transcription following zinc treatment (Figure 2 ). We speculate that the NGF transgene may have inserted into another transcriptionally active endogeneous gene in this transfectant clone; during the course of integration, the metallothionein promoter and/or the NGF transcription unit may have become disrupted, thereby disabling the potential production of bioactive NGF. Other c-fos mRNA species (depicted by differences in mRNA size) may also be induced by the activation of NGF.
Tyrosine hydroxylase-like ('TH-like') immunoreactivity was detected within neuron-like perikarya and processes of host caudate-putamen, following implantation of both NP33 and NP15 transfectants (Table 2; Figure 3) . While a large number of the 'TH-like' immunoreactive fibers detected in this region are probably derived from the host's substantia nigra (part of the nigrostriatal dopaminergic system), the presence of TH-reactive perikarya in the region of the implant suggests their identity as the injected neurotransformed PC12 transfectants (since this 
a PC12 cells were implanted into caudate-putamen of adult (200 g) Sprague-Dawley rats using a Kopf stereotactic frame. All rats were grafted unilaterally into the left caudate-putamen. The incisor bar was adjusted until the heights of the lambda and bregma skull points were equal. The coordinates employed (0.25 mm lateral to the sagittal suture, 0.02 mm anterior to the bregma and 0.6 mm from the surface of the skull) were obtained from the stereotactic atlas of the rat brain. 111 Burr holes were drilled into the skull, and cells (50 000 cells in 10 l of modified L-15 medium) were injected into the caudate-putamen using a stereotactic frame-mounted Hamilton syringe. Following implantation, the burr hole was sealed with bone wax, the skin incision closed, and the rats were administered with bicillin (2000 U) and allowed to recover on heating pads. Rats were preloaded with zinc (100 mg/kg) in their solid food for 1 month before implantation and maintained on the same zinc-supplemented diet for an additional 5 weeks after implantation. All rats were perfused at 5 weeks after transplantation. All rats implanted with MEP4-PC12 cells either died (n = 3) or in the case of survivors (at time of death; n = 4) developed a significant tumor mass at the site of implantation. Central necrosis was also observed in the tumor masses. In the case of the survivors, we speculate that the rate of cell division exceeds the rate of cell degeneration, resulting in tumor formation. d Experiments examining tyrosine hydroxylase were not done (ND) for this series of rats. e Technical limitations with the use of the monoclonal NGF antibody precluded detection of low levels of NGF. This Table was anatomical area contains few TH-positive neurons, which are smaller and morphologically distinguishable from PC12 cells). The expression of the NGF transgene product, as shown by the 'NGF-like' immunoreactivity within the neuron-like perikarya of this brain region ( Figure 3B ) also provides additional support as to their PC12 origin.
Our study demonstrates that tyrosine hydroxylase or 'TH-like' activity is maintained in rat striatal PC12 grafts for 5 weeks after transplantation. Our observations are consistent with other investigators 107 that report variable, but measurable, tyrosine hydroxylase expression in PC12 rat striatal implants. In contrast, other studies demonstrate that TH mRNAs in PC12 cells are down-regulated (two-fold reduction) following a 2-week treatment of NGF 108 and that TH activity is down-regulated in PC12 cells genetically modified to express NGF and implanted in the mouse striatus. 102, 103 In these latter studies, the implanted cells lost their catecholaminergic phenotype in vivo, and were not useful in the potential replacement of nigrostriatal neurons. While not every implanted NP33 cell stained positive for tyrosine hydroxylase in our study, some cells express TH or 'TH-like' activity, suggesting that the NP33 implant retained its catecholaminergic phenotype. Alternatively, we cannot preclude the possibility that PC12 cellular variants, which do not express tyrosine hydroxylase in vitro, are undergoing selective survival after implantation, and that the implant at some later time, if left unharvested, may lose its catecholaminergic phenotype.
Interestingly, we have noticed some evidence of graft rejection at the host-graft interface, and observed some degree of tissue necrosis and host inflammatory cell infiltration. While the presence of inflammatory cells in this region could in part be attributed to break-down of the blood-brain barrier from the surgical trauma of transplantation, it is also possible that these morphological changes represent an immune-mediated graft rejection. This finding is not surprising in light of other reports 104 describing the limited survival of allogeneic PC12 cell grafts in rat brain. This limited survival is presumably due to rejection of the graft by the immune system; PC12 graft survival can be enhanced with the use of immunosuppressive drugs, such as cyclosporin, or with the use of semi-permeable polymer encapsulation of the implanted cells. 104 We also cannot rule out that other factors important in achieving long-term expression of transgenes, such as promoter attenuation, or elimination of the transduced recombinant DNA or product, may be occurring in the brain implants. In the case of some viral and cellular promoters, promoter attenuation may be due to cytokine (eg interferon (IFN)-␥ and tumor necrosis factor-␣) interaction in vivo; in some cases, administration of neutralizing antibodies to IFN has resulted in the enhancement of transgene expression.
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Concluding remarks
Gene therapy and genetic transfer approaches have received recent consideration as potential treatment modalities for human central and peripheral nervous system neurodegenerative disorders. [8] [9] [10] Transplantation of genetically modified cells into the brain represents a promising strategy for the delivery and expression of specific neurotrophic factors, neurotransmitter-synthesizing enzymes, and cellular regulatory proteins for intervention in neurodegenerative diseases. The use of specific regulatable promoters may also provide potential transcriptional control to permit predictable expression of transgenes in vivo. Although many inducible expression systems are available that demonstrate great potential in vitro or within test animals, further research needs to be conducted to develop nonimmunogenic systems and benign inducers in humans. With the rapid development of synthetic regulatable systems, it appears likely that spatial and temporal control of transgene expression may be available in the near future for potential treatment of human neurodegenerative disorders.
